A case of solitary plasmacytoma of bone showing co-expression of both immunoglobulin light chains.

Eur J Med Res

Department of Diagnostic Pathology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8577, Japan.

Published: December 2021


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Solitary plasmacytoma of bone (SPB) is a rare plasma cell neoplasm. It arises in bone as a single locus in the absence of any plasma cell myeloma lesions. Plasma cell neoplasms intrinsically express only one immunoglobulin light chain (IgL)-kappa or lambda-and using this fact, kappa/lambda deviation is the decisive factor for diagnosis. Co-expression of both IgLs in a single tumor cell is extremely rare.

Case Presentation: We report a case of SPB that arose in the vertebra of a 52-year-old Japanese woman. Histologically, the resected mass showed diffuse plasma cell proliferation. Dual IgL expression was detected by flow cytometry, immunohistochemistry, and in situ hybridization (ISH) targeting IgL mRNA.

Conclusion: We have presented an extremely rare case of SPB showing dual expression of kappa and lambda IgLs. This unusual case of plasma cell neoplasia might represent a possible exceptional example of failure of "IgL isotypic exclusion."

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686560PMC
http://dx.doi.org/10.1186/s40001-021-00621-8DOI Listing

Publication Analysis

Top Keywords

plasma cell
20
solitary plasmacytoma
8
plasmacytoma bone
8
immunoglobulin light
8
case spb
8
cell
6
plasma
5
case
4
case solitary
4
bone showing
4

Similar Publications

Introduction: Targeted infection imaging is crucial for accurate diagnosis in postpartum women. This project uses 99mTc-labeled cefixime to develop a radiopharmaceutical for detecting, distinguishing, and treating infections and abscesses in women.

Method: Technetium (TcO4-) chelated with cefixime, reduced by stannous chloride, confirmed via thin-layer chromatography.

View Article and Find Full Text PDF

Background: Atherosclerosis (AS) is a leading risk factor for cardiovascular diseases globally, characterised by the accumulation of lipids and cholesterol in arterial walls, causing vascular narrowing and sclerosis along with chronic inflammation; this leads to increased risk of heart disease and stroke, significantly impacting patients' health. Danxia Tiaoban Decoction (DXTB), a traditional Chinese medicine (TCM) formula, has demonstrated positive clinical effects in treating AS; however, its mechanisms of action remain unclear.

Objective: To explore the potential mechanisms of action of DXTB in treating AS through multi-omics integration and experimental validation.

View Article and Find Full Text PDF

B cells play a critical role in tumor immunity, with their presence associated with improved prognosis in various cancers, including endometrial cancer (EC). However, the nature of the B cell response within the tumor microenvironment (TME) remains incompletely understood. In this study, we conducted single-cell analyses of B cells and CD4+ T cells in the TME of EC.

View Article and Find Full Text PDF

Boosting biocompatibility and minimizing inflammation in electrospun polyvinylidene fluoride (PVDF) cardiac patches through optimized low-pressure plasma treatment.

Biomater Adv

September 2025

Department of Applied Science and Technology (DISAT), Politecnico di Torino, Corso Duca Degli Abruzzi 24, 10129 Torino, Italy.

Tailoring surface characteristics is key to guiding scaffold interaction with the biological environment, promoting successful biointegration while minimizing immune responses and inflammation. In cardiac tissue engineering, polyvinylidene fluoride (PVDF) is a material of choice for its intrinsic piezoelectric properties, which can be enhanced through electrospinning, also enabling the fabrication of nanofibrous structures mimicking native tissue. However, the inherent hydrophobicity of PVDF can hinder its integration with biological tissues.

View Article and Find Full Text PDF

Purpose: We investigated whether EML4-ALK fusions and mutations in pre-treatment plasma ctDNA predicted time to treatment discontinuation (TTD) in ALK-positive non-small cell lung cancer (ALK+ NSCLC) patients initiating first-line alectinib and evaluated clinical characteristics influencing TTD.

Materials & Methods: 42 patients from five Danish public oncology departments with previously untreated, metastatic ALK+ NSCLC were included in the study. All patients received alectinib, a second-generation ALK inhibitor, as their first-line treatment.

View Article and Find Full Text PDF